5.28
-0.06 (-1.07%)
| Penutupan Terdahulu | 5.34 |
| Buka | 5.27 |
| Jumlah Dagangan | 9,209 |
| Purata Dagangan (3B) | 38,886 |
| Modal Pasaran | 24,161,468 |
| Harga / Jualan (P/S) | 3.40 |
| Harga / Buku (P/B) | 1.46 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 - 16 May 2025 |
| Margin Operasi (TTM) | -412.44% |
| EPS Cair (TTM) | -46.59 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -51.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 6,223.48% |
| Nisbah Semasa (MRQ) | 11.03 |
| Aliran Tunai Operasi (OCF TTM) | -60.92 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -44.23 M |
| Pulangan Atas Aset (ROA TTM) | -41.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -270.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Cara Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | 1.00 |
|
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 13.07% |
| % Dimiliki oleh Institusi | 24.17% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |